Wall Street Analysts Think biote Corp. (BTMD) Could Surge 25.44%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable biote Corp. (BTMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Biote Corp. Announces Strategic Sales Head Departure and Compensation Package The latest update is out from biote (BTMD). Biote Corp. recently announced the termination of Mary Puncochar, their Head of Strategic Sales & Busin…
biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains? biote Corp. (BTMD) shares ended the last trading session 10.4% higher at $7.30. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock''s 12% gain
biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains? biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Roth/MKM ups Biote Corp shares target, highlights share repurchase strategy https://www.investing.com/news/company-news/rothmkm-ups-biote-corp-shares-target-highlights-share-repurchase-strategy-93CH-3491826
Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz, stockholder of Biote, to resolve litigation (“Donovitz Litigation”). For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class.
biote Corp. (BTMD) Q1 2024 Earnings Call Transcript biote Corp. (NASDAQ:BTMD ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Ross McQuivey - Chief Medical Officer Conference Call Participants Les Sulewski - Truist Securities Jonna Kim - TD Cowen Kaumil Gajrawala - Jefferies George Kelly - ROTH MKM Operator Good day, and welcome to the Biote First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.